Unknown

Dataset Information

0

Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism.


ABSTRACT: The Akt/mTORC1 pathway plays a central role in the activation of Warburg effect in cancer. Here, we present for the first time that halofuginone (HF) treatment inhibits colorectal cancer (CRC) growth both in vitro and in vivo through regulation of Akt/mTORC1 signaling pathway. Halofuginone treatment of human CRC cells inhibited cell proliferation, induced the generation of reactive oxygen species and apoptosis. As expected, reduced level of NADPH was also observed, at least in part due to inactivation of glucose-6-phosphate dehydrogenase in pentose phosphate pathway upon HF treatment. Given these findings, we further investigated metabolic regulation of HF through Akt/mTORC1-mediated aerobic glycolysis and found that HF downregulated Akt/mTORC1 signaling pathway. Moreover, metabolomics delineated the slower rates in both glycolytic flux and glucose-derived tricarboxylic acid cycle flux. Meanwhile, both glucose transporter GLUT1 and hexokinase-2 in glycolysis were suppressed in CRC cells upon HF treatment, to support our notion that HF regulates Akt/mTORC1 signaling pathway to dampen glucose uptake and glycolysis in CRC cells. Furthermore, HF retarded tumor growth in nude mice inoculated with HCT116 cells, showing the anticancer activity of HF through metabolic regulation of Akt/mTORC1 in CRC.

SUBMITTER: Chen GQ 

PROVIDER: S-EPMC4695176 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism.

Chen Guo-Qing GQ   Tang Cheng-Fang CF   Shi Xiao-Ke XK   Lin Cheng-Yuan CY   Fatima Sarwat S   Pan Xiao-Hua XH   Yang Da-Jian DJ   Zhang Ge G   Lu Ai-Ping AP   Lin Shu-Hai SH   Bian Zhao-Xiang ZX  

Oncotarget 20150901 27


The Akt/mTORC1 pathway plays a central role in the activation of Warburg effect in cancer. Here, we present for the first time that halofuginone (HF) treatment inhibits colorectal cancer (CRC) growth both in vitro and in vivo through regulation of Akt/mTORC1 signaling pathway. Halofuginone treatment of human CRC cells inhibited cell proliferation, induced the generation of reactive oxygen species and apoptosis. As expected, reduced level of NADPH was also observed, at least in part due to inacti  ...[more]

Similar Datasets

| S-EPMC5010978 | biostudies-literature
| S-EPMC6958723 | biostudies-literature
2020-03-24 | GSE147413 | GEO
| S-EPMC7519326 | biostudies-literature
| S-EPMC8234711 | biostudies-literature
| S-EPMC6815449 | biostudies-literature
| S-EPMC5835694 | biostudies-literature
| S-EPMC8039130 | biostudies-literature
| S-EPMC7858139 | biostudies-literature
| S-EPMC9134896 | biostudies-literature